3.19
price up icon0.31%   0.010
 
loading
전일 마감가:
$3.18
열려 있는:
$3.18
하루 거래량:
422.94K
Relative Volume:
0.47
시가총액:
$526.53M
수익:
-
순이익/손실:
$-54.70M
주가수익비율:
-9.6667
EPS:
-0.33
순현금흐름:
$-51.36M
1주 성능:
+4.59%
1개월 성능:
+9.62%
6개월 성능:
-9.38%
1년 성능:
-27.66%
1일 변동 폭
Value
$3.14
$3.26
1주일 범위
Value
$3.07
$3.385
52주 변동 폭
Value
$2.31
$5.31

사바라 Stock (SVRA) Company Profile

Name
명칭
Savara Inc
Name
전화
51285113796
Name
주소
6836 BEE CAVE ROAD, AUSTIN, TX
Name
직원
59
Name
트위터
@SavaraPharma
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
SVRA's Discussions on Twitter

SVRA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SVRA
Savara Inc
3.19 526.53M 0 -54.70M -51.36M -0.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

사바라 Stock (SVRA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-20 개시 Wells Fargo Overweight
2024-11-13 다운그레이드 Evercore ISI Outperform → In-line
2024-02-15 개시 JMP Securities Mkt Outperform
2023-11-07 개시 Guggenheim Buy
2023-05-16 업그레이드 Jefferies Hold → Buy
2023-03-31 다운그레이드 Jefferies Buy → Hold
2021-03-16 개시 Piper Sandler Overweight
2021-03-15 개시 Oppenheimer Outperform
2019-06-13 재확인 H.C. Wainwright Buy
2019-06-13 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2019-06-13 다운그레이드 Ladenburg Thalmann Buy → Neutral
2018-08-13 재개 ROTH Capital Neutral
2018-01-03 개시 Ladenburg Thalmann Buy
2017-09-27 재개 ROTH Capital Buy
2017-09-22 개시 Jefferies Buy
2017-09-11 개시 JMP Securities Mkt Outperform
모두보기

사바라 주식(SVRA)의 최신 뉴스

pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

Savara Inc (NASDAQ:SVRA) Shares Purchased by Geode Capital Management LLC - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

JMP maintains $10 target on Savara stock post-BLA submission By Investing.com - Investing.com Nigeria

Apr 23, 2025
pulisher
Apr 23, 2025

Examining Savara Inc (SVRA) more closely is necessary - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

JMP maintains $10 target on Savara stock post-BLA submission - Investing.com

Apr 23, 2025
pulisher
Apr 21, 2025

Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha

Apr 21, 2025
pulisher
Apr 20, 2025

Savara Inc. Announces Equity Awards for New Employees - MSN

Apr 20, 2025
pulisher
Apr 20, 2025

JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World

Apr 20, 2025
pulisher
Apr 15, 2025

Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Savara Announces New Employment Inducement Grant - Bluefield Daily Telegraph

Apr 11, 2025
pulisher
Apr 11, 2025

Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN

Apr 10, 2025
pulisher
Apr 07, 2025

Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Savara to present aPAP treatment study at medical congresses - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan

Apr 07, 2025
pulisher
Apr 06, 2025

259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World

Apr 06, 2025
pulisher
Apr 04, 2025

Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN

Apr 04, 2025
pulisher
Apr 03, 2025

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st

Apr 03, 2025
pulisher
Apr 02, 2025

Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com

Apr 02, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - marketscreener.com

Apr 01, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock - Investing.com India

Apr 01, 2025
pulisher
Mar 31, 2025

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

Savara Inc ends sales agreement with Evercore By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Savara Inc ends sales agreement with Evercore - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Savara enters loan and security agreement with Hercules Capital - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 28, 2025

사바라 (SVRA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
자본화:     |  볼륨(24시간):